Tetrahydrocannabivarin THCV Clinical Research

THCV Clinical Research



Δ9-Tetrahydrocannabivarin THCV: a commentary on potential therapeutic benefit for the management of obesity and diabetes

Amos Abioye, Oladapo Ayodele, Aleksandra Marinkovic, Risha Patidar, Adeola Akinwekomi, Adekunle Sanyaolu | January 31, 2020 | Journal of Cannabis Research | Full Text THCV Type 2 Diabetes

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett, E. Louise Thomas, Colin Stott, Jimmy D. Bell, Saoirse E. O’Sullivan, Garry D. Tan | September 13, 2016 | Diabetes CareVolume 39, Issue 10 | Full Text THCV Food Aversion

Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers

Luke Tudge, MSc, Clare Williams, BSc, Philip J. Cowen, MD, FRCPsych, Ciara McCabe, PhD | April, 2015 | International Journal of Neuropsychopharmacology, 2015, 1–9 | Full Text Delta-9 THCV insulin sensitivity

The cannabinoid Δ9-tetrahydrocannabivarin THCV ameliorates insulin sensitivity in two mouse models of obesity

E T Wargent, M S Zaibi, C Silvestri, D C Hislop, C J Stocker, C G Stott, G W Guy, M Duncan, V Di Marzo, M A Cawthorne | May 2013 | Nutrition & Diabetes | Full Text THCV Fasting Mice

Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice

Gernot Riedel, Paola Fadda, Susan McKillop-Smith, Roger G Pertwee, Bettina Platt, Lianne Robinson | April 2009 | British Journal of Pharmacology | Full Text THCV Pharmacology

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

R G Pertwee | January 2008 | British Journal of Pharmacology | Full Text THCV cannabinoid

The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo

R G Pertwe, A Thomas, L A Stevenson, R A Ross, S A Varvel, A H Lichtman, B R Martin, R K Razdan | January 22, 2007 | British Journal of Pharmacology | Full Text Delta-9 THCV

Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

Adèle Thomas, Lesley A Stevenson, Kerrie N Wease, Martin R Price, Gemma Baillie, Ruth A Ross, Roger G Pertwee1 | October 3, 2005 | British Journal of Pharmacology | Full Text THCV Diabetes